PD-1 blocking antibody

Phase 3Small molecule

PD-1 blocking antibody is one of 107 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Rectal Cancer PatientsRecruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Rectal Cancer PatientsPhase 1

Recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

PD-1 blocking antibody

SSun Yat-sen University

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

MS Contin

1 4

Medrol

Pfizer

Preclinical

1 5

Byetta

AstraZeneca

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

ABI-007

Bristol-Myers Squibb

Preclinical

2 8

Active Comparator

Moderna

Preclinical

1 9

LDE225

Novartis

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Biomarker

NCT04605562

Q1 2027

Phase 3Active, not recruiting

Nasopharyngeal Carcinoma

NCT04907370

Q4 2028

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT03907826

Q1 2030

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT06239727

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma5 trials

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting·SSun Yat-sen University·Phase 3·NCT06239727·593 enrolled

PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT04907370·532 enrolled

Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Completed·SSun Yat-sen University·Phase 2·NCT03984357·152 enrolled

Show 2 more trials

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT03930498·68 enrolled

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting·SSun Yat-sen University·Phase 3·NCT03907826·212 enrolled

Colorectal Cancer2 trials

PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT03638297·29 enrolled

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04715633·53 enrolled

Oligometastatic1 trial

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Unknown status·SSun Yat-sen University·Phase 2·NCT05626569·40 enrolled

Biomarker1 trial

Umbrella Biomarker-Guided Therapy in NPC

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT04605562·206 enrolled

Pancreatic Cancer1 trial

Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer

Completed·PPeking University Third Hospital··NCT06195254·19 enrolled

2 more indications

Advanced Solid Tumors1 trial

Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients

Unknown status·RRuijin Hospital·Phase 2·NCT05097781·55 enrolled

Rectal Cancer Patients1 trial

A Phase I Study of the Safety and Efficacy of a Modified Vaccinia Virus (BT-001) Delivered by Endoscopic Intra-tumoural Injection Followed by Systemic Antiprogammed Death-1 (Anti-PD-1) Antibodies in Patients With Localised Rectal Cancer With Proficient Mismatch Repair (pMMR)

Recruiting·HHenry Smith·Phase 1·NCT07687875·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for PD-1 blocking antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-1 blocking antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-1 blocking antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

PD-1 blocking antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2028

Q1 2030

Trials by Indication[1]

Nasopharyngeal Carcinoma5 trials

Colorectal Cancer2 trials

Oligometastatic1 trial

Biomarker1 trial

Pancreatic Cancer1 trial

Advanced Solid Tumors1 trial

Rectal Cancer Patients1 trial

References

Drug Info

Quick Facts

Related News